Found: 7
Select item for more details and to access through your institution.
How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future.
- Published in:
- Journal of Market Access & Health Policy, 2020, v. 8, n. 1, p. 1, doi. 10.1080/20016689.2020.1719588
- By:
- Publication type:
- Article
Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
- Published in:
- Applied Health Economics & Health Policy, 2019, v. 17, n. 5, p. 723, doi. 10.1007/s40258-019-00491-6
- By:
- Publication type:
- Article
A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable <italic>Haemophilus influenzae</italic> Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand
- Published in:
- Applied Health Economics & Health Policy, 2018, v. 16, n. 3, p. 331, doi. 10.1007/s40258-018-0387-5
- By:
- Publication type:
- Article
The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis.
- Published in:
- Dermatology & Therapy, 2018, v. 8, n. 2, p. 269, doi. 10.1007/s13555-018-0236-3
- By:
- Publication type:
- Article
Comment on: ‘Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada’, Wilson et al., 22 June 2018.
- Published in:
- Infectious Diseases & Therapy, 2018, v. 7, n. 4, p. 535, doi. 10.1007/s40121-018-0220-3
- By:
- Publication type:
- Article
The temporal impact of aging on the burden of herpes zoster.
- Published in:
- 2017
- By:
- Publication type:
- journal article